Losectil MUPS40 mg

Losectil MUPS is indicated for conditions caused or aggravated by excess gastric acid secretion. Evidence strength varies by indication:

• Established/FDA-approved: symptomatic GERD; healing and maintenance of healing of erosive esophagitis; active duodenal ulcer; active benign gastric ulcer; pathological hypersecretory conditions such as Zollinger-Ellison syndrome.
• Combination therapy (requires other agents): Helicobacter pylori eradication, used together with antibiotics (e.g., clarithromycin and amoxicillin) as part of guideline-recommended triple or dual therapy — Losectil MUPS alone does not eradicate H. pylori.
• Guideline-supported adjunct use: prevention of NSAID-associated gastric/duodenal ulcers in patients requiring continued NSAID therapy, particularly those at higher GI risk.

Each Omeprazole [Multiple-Unit Pellet System] tablet contains omeprazole formulated as thousands of tiny enteric-coated pellets compressed together into a Multiple-Unit Pellet System (MUPS) tablet. Once the tablet contacts moisture (in the stomach or when dispersed in water), it rapidly breaks apart into the individual enteric-coated pellets, each of which protects the omeprazole from gastric acid until it reaches the small intestine for absorption.

Losectil MUPS is a proton pump inhibitor (PPI) that reduces gastric acid secretion. It is formulated using Multiple-Unit Pellet System (MUPS) technology, in which the tablet is made of many small enteric-coated pellets compressed into a single tablet. This design gives Losectil MUPS the convenience of a standard tablet while retaining the flexibility of a multiparticulate formulation: the tablet can be swallowed whole, or dispersed in a small amount of non-carbonated water (or apple juice) for patients who have difficulty swallowing tablets/capsules or who require administration through a nasogastric or gastric feeding tube, without compromising the enteric coating that protects the drug from degradation by stomach acid.

Losectil MUPS is used to treat conditions caused or worsened by excess stomach acid, including gastroesophageal reflux disease (GERD), erosive esophagitis, gastric and duodenal ulcers, and, as part of combination regimens, Helicobacter pylori eradication and pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

Losectil MUPS belongs to the Proton Pump Inhibitor (PPI) class of anti-secretory, acid-suppressing agents.

Omeprazole [Multiple-Unit Pellet System] is a prodrug that is a weak base. After absorption into the systemic circulation, it accumulates in the acidic secretory canaliculi of the gastric parietal cell, where it is protonated and converted to its active sulfenamide form. This active form binds covalently to cysteine residues on the H⁺/K⁺-ATPase (the "proton pump") on the luminal surface of the parietal cell membrane, irreversibly inhibiting this final common pathway of gastric acid secretion. Because inhibition is irreversible, acid suppression persists until new proton pump molecules are synthesized, producing an antisecretory effect that outlasts the drug's short plasma half-life (approximately 0.5–1 hour) and typically requires 3–5 days of once-daily dosing to reach maximal effect.

Omeprazole [Multiple-Unit Pellet System] is metabolized in the liver mainly by the cytochrome P450 enzyme CYP2C19, with a minor contribution from CYP3A4.

Losectil MUPS should be swallowed whole with water, on an empty stomach, 30–60 minutes before a meal. If swallowing is difficult, or for feeding-tube administration, the tablet can be dispersed in a small amount of non-carbonated water and given promptly without crushing or chewing the pellets, exactly as directed by a physician or pharmacist.

Losectil MUPS inhibits CYP2C19 and increases gastric pH, giving rise to several clinically important interactions:

• Rilpivirine-containing products: Losectil MUPS substantially reduces rilpivirine absorption and plasma concentrations, risking loss of antiretroviral efficacy and resistance; concurrent use is contraindicated (see Contraindications).
• Clopidogrel: Losectil MUPS inhibits CYP2C19-mediated conversion of clopidogrel to its active metabolite, potentially reducing clopidogrel's antiplatelet effect; concomitant use should generally be avoided, and an alternative acid-suppressing agent or antiplatelet strategy considered.
• Warfarin: may increase INR and prothrombin time, raising bleeding risk; monitor coagulation parameters if used together.
• Methotrexate (high-dose): Losectil MUPS may elevate and prolong serum methotrexate (and its metabolite) levels, increasing toxicity risk; temporary withdrawal of Losectil MUPS may be considered during high-dose methotrexate therapy.
• Drugs requiring acidic gastric pH for absorption (e.g., ketoconazole, itraconazole, iron salts, certain HIV antiretrovirals such as atazanavir/nelfinavir): Losectil MUPS can substantially reduce their absorption and efficacy.
• CYP2C19/CYP3A4 substrates (e.g., diazepam, phenytoin, cilostazol, tacrolimus, voriconazole): Losectil MUPS may alter their plasma levels; dose adjustment or monitoring may be needed.
• CYP inducers (e.g., rifampicin, St. John's Wort): may reduce omeprazole levels and effectiveness of Losectil MUPS.

Common (may affect up to 1 in 10 people): headache, abdominal pain, nausea, diarrhea, vomiting, flatulence, and constipation.

Less common: dizziness, rash, pruritus, dry mouth, and elevated liver enzymes.

Rare but serious (seek medical attention promptly if these occur): severe diarrhea due to Clostridioides difficile infection, low magnesium levels (hypomagnesemia — can present as muscle spasms, irregular heartbeat, or seizures with long-term use), bone fracture of the hip, wrist, or spine with prolonged high-dose use, vitamin B12 deficiency with long-term use, cutaneous or systemic lupus erythematosus, severe skin reactions (e.g., Stevens-Johnson syndrome), acute interstitial nephritis, pancreatitis, and liver failure. See Precautions and Warnings for further detail on long-term risks.

Pregnancy: Available epidemiological data have not shown an increased risk of major congenital malformations with omeprazole use during pregnancy; however, Losectil MUPS should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Use should always be under the guidance of a physician.

Lactation: Omeprazole passes into breast milk in small amounts. Because of a theoretical risk to the nursing infant, a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Losectil MUPS, taking into account the importance of treatment to the mother.

Masking of gastric malignancy: Symptomatic response to Losectil MUPS does not exclude the presence of gastric malignancy. Alarm features (unintentional weight loss, recurrent vomiting, dysphagia, GI bleeding, or anemia) should be evaluated before or promptly after starting therapy, and symptom improvement should not delay further investigation if these features are present.

Bone fracture: Long-term use, particularly at high doses and for more than a year, has been associated with an increased risk of fracture of the hip, wrist, and spine. Patients at risk of osteoporosis should be managed per standard care while on long-term therapy.

Hypomagnesemia: Prolonged treatment (generally beyond 3 months, and especially beyond 1 year) can cause low serum magnesium, which may be severe and can present as tetany, arrhythmias, or seizures. Risk is higher with concurrent diuretics or digoxin; healthcare providers may check magnesium levels before and periodically during prolonged therapy.

Clostridioides difficile-associated diarrhea: Losectil MUPS may increase the risk of C. difficile infection of the intestine; consider this diagnosis in patients who develop persistent diarrhea that does not improve.

Vitamin B12 deficiency: Long-term therapy (more than 3 years) may reduce absorption of vitamin B12 due to hypo- or achlorhydria.

Clopidogrel: Concomitant use may reduce clopidogrel's antiplatelet effectiveness (see Interaction); avoid combined use when possible.

Hepatic/renal impairment: Use with caution and consider dose reduction in patients with severe hepatic impairment; no adjustment is generally required for renal impairment.

Losectil MUPS should be used at the lowest effective dose for the shortest duration appropriate to the condition being treated, with periodic reassessment for long-term use.

Reported symptoms of Losectil MUPS overdose have included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other transient effects; no specific antidote is known. If an overdose of Losectil MUPS is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Treatment is supportive and symptomatic; Losectil MUPS is not efficiently removed by hemodialysis due to high protein binding.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No dosage adjustment is generally required based on age alone, but elderly patients on long-term therapy should be monitored for bone fracture, hypomagnesemia, and B12 deficiency risks (see Precautions and Warnings).

Pediatric: Losectil MUPS is approved for GERD and erosive esophagitis in children 2 years and older using weight-based dosing; safety and efficacy in children under 1 year of age have not been established.

Hepatic impairment: Consider dose reduction in severe hepatic impairment.

Renal impairment: No dose adjustment generally required.

Pregnancy and lactation: See Pregnancy and Lactation section.

Duration of Losectil MUPS therapy depends on indication: typically 4 weeks for duodenal ulcer, 4–8 weeks for gastric ulcer/GERD/erosive esophagitis, 10–14 days as part of H. pylori eradication regimens, and potentially long-term/indefinite for maintenance of erosive esophagitis healing or hypersecretory conditions such as Zollinger-Ellison syndrome, under ongoing physician supervision. See Dosage and Administration for the per-indication table.

Proton Pump Inhibitors (PPIs)

Omeprazole [Multiple-Unit Pellet System] is a prodrug activated by acid in the parietal cell's secretory canaliculus, where it irreversibly binds and inhibits the gastric H⁺/K⁺-ATPase (proton pump), the final step in gastric acid secretion, resulting in profound and long-lasting suppression of both basal and stimulated gastric acid output.

C

Losectil MUPS is approved for the treatment of GERD and erosive esophagitis in children 2 years of age and older, dosed by body weight (approximately 10 mg once daily under 20 kg, 20 mg once daily at 20 kg or more). Safety and efficacy of Losectil MUPS have not been established in children under 1 year of age, and data in children 1–2 years old are limited; use in this younger age group should be individualized and supervised by a pediatrician. The MUPS formulation may be dispersed in water for children who cannot swallow tablets, under medical guidance.